ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 95 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $1,164,000 | +18.4% | 58,324 | +3.9% | 0.00% | -50.0% |
| Q1 2018 | $983,000 | -96.9% | 56,109 | -95.6% | 0.00% | -94.3% |
| Q4 2017 | $31,656,000 | +79.9% | 1,283,684 | +88.3% | 0.04% | -14.6% |
| Q3 2017 | $17,598,000 | +21.3% | 681,819 | +27.5% | 0.04% | +20.6% |
| Q2 2017 | $14,504,000 | +246.7% | 534,804 | +281.3% | 0.03% | +240.0% |
| Q1 2017 | $4,183,000 | – | 140,268 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |